OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 1,086.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 135,856 shares of the biotechnology company’s stock after acquiring an additional 124,410 shares during the quarter. SG Americas Securities LLC’s holdings in OPKO Health were worth $202,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Rubric Capital Management LP increased its position in shares of OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after buying an additional 39,486,490 shares in the last quarter. Y.D. More Investments Ltd purchased a new stake in OPKO Health during the 2nd quarter worth about $1,840,000. Squarepoint Ops LLC purchased a new stake in OPKO Health during the 2nd quarter worth about $592,000. Lazard Asset Management LLC purchased a new stake in OPKO Health during the 1st quarter worth about $258,000. Finally, AWM Investment Company Inc. increased its position in OPKO Health by 18.2% during the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock worth $1,560,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on OPK shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. StockNews.com raised OPKO Health to a “sell” rating in a research note on Saturday, July 27th. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Friday, September 20th.

OPKO Health Stock Performance

OPKO Health stock opened at $1.46 on Wednesday. The stock’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.40. The firm has a market capitalization of $1.02 billion, a PE ratio of -4.17 and a beta of 1.63. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $1.75.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.08. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The company had revenue of $182.20 million for the quarter, compared to the consensus estimate of $184.70 million. During the same period in the previous year, the business earned ($0.03) EPS. OPKO Health’s revenue for the quarter was down 31.3% compared to the same quarter last year. As a group, sell-side analysts expect that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other OPKO Health news, major shareholder Opko Health, Inc. sold 100,000 shares of OPKO Health stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the sale, the insider now directly owns 2,871,570 shares in the company, valued at $91,373,357.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 461,444 shares of company stock worth $15,335,127 in the last three months. 47.26% of the stock is owned by insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.